• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical and quality of life assessment in patients with latex allergy during COVID-19 pandemic: Possible protective role of continuous latex immunotherapy
Conclusions: Our study is the first that investigated the clinical and quality of life effects of COVID-19 pandemic in NRLA patients.PMID:35575237 | PMC:PMC9111907 | DOI:10.1177/03946320221100367
Source: International Journal of Immunopathology and Pharmacology - May 16, 2022 Category: Allergy & Immunology Authors: Alessia Di Rienzo Sara Urbani David Longhino Caterina Sarnari Alessandro Buonomo Angela Rizzi Arianna Aruanno Eleonora Nucera Source Type: research

Allergy and Immunotherapy During the Pandemic
AbstractPurpose of ReviewTo summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic.Recent FindingsAt the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now with medical practices reopening, allergists must establish plans and protocols for resuming care of allergy patients, including strategies for restarting allergen immunotherapy. While there are no published evidence-based protocols for resuming allergen immunotherapy, limited scientific data and expert opinion suggest that th...
Source: Current Otorhinolaryngology Reports - March 9, 2022 Category: ENT & OMF Source Type: research

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy
AbstractThe current COVID-19 global pandemic poses immense challenges to global health, largely due to the difficulty to detect infection in the early stages of the disease, as well as the current lack of effective antiviral therapy. Research and understanding of the human immune system can provide important theoretical and technical support for the clinical diagnosis and treatment of COVID-19, the clinical implementations of which include immunoassays and immunotherapy, which play a crucial role in the fight against the pandemic. This review consolidates the current scientific evidence for immunoassay, which includes mult...
Source: Clinical Reviews in Allergy and Immunology - January 15, 2022 Category: Allergy & Immunology Source Type: research

Antibody therapy for COVID-19
Purpose of review To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. Recent findings Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results. Summary Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding...
Source: Current Opinion in Allergy and Clinical Immunology - November 8, 2021 Category: Allergy & Immunology Tags: PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles Source Type: research

Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy
Purpose of review Molecular forms of allergen-specific immunotherapy (AIT) are continuously emerging to improve the efficacy of the treatment, to shorten the duration of protocols and to prevent any side effects. The present review covers the recent progress in the development of AIT based on nucleic acid encoding allergens or CpG oligodeoxynucleotides (CpG-ODN). Recent findings Therapeutic vaccinations with plasmid deoxyribonucleic acid (DNA) encoding major shrimp Met e 1 or insect For t 2 allergen were effective for the treatment of food or insect bite allergy in respective animal models. DNA expressing hypoal...
Source: Current Opinion in Allergy and Clinical Immunology - November 8, 2021 Category: Allergy & Immunology Tags: IMMUNOTHERAPY AND NEW TREATMENTS: Edited by Giovanni Passalacqua and Robert Bush Source Type: research

Biological therapies, asthma and coronavirus disease 2019
Purpose of review As of June 2021, coronavirus disease 2019 (COVID-19) exceeded 180 million reported cases and was responsible for almost 4 million deaths globally. Asthma affects approximately 262 million people worldwide and is an important cause of morbidity and mortality. Presently, it appears asthma is neither associated with an increased risk of contracting COVID-19 nor with a risk of severe COVID-19 or COVID-19 related death. Regarding the severe asthma patients on biologics, questions remain. The purpose of this review is to discuss the evidence regarding the relationship between asthma, biologics and COVID-19....
Source: Current Opinion in Allergy and Clinical Immunology - November 8, 2021 Category: Allergy & Immunology Tags: IMMUNOTHERAPY AND NEW TREATMENTS: Edited by Giovanni Passalacqua and Robert Bush Source Type: research

Antihistamine Premedication Improves Safety and Efficacy of Allergen Immunotherapy
CONCLUSION: Antihistamine premedication can significantly improve safety and efficacy of AIT by reducing frequency and severity of SAR and increasing TMD.PMID:34052425 | DOI:10.1016/j.anai.2021.05.023
Source: Annals of Allergy, Asthma and Immunology - May 30, 2021 Category: Allergy & Immunology Authors: Li Wang Chengshuo Wang Hongfei Lou Luo Zhang Source Type: research

Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
CONCLUSIONS Our data confirm, for what we believe is the first time, the existence of unique memory CD4+ T cell clonotypes crossrecognizing SARS-CoV-2 and CCCs. The lower avidity of crossreactive TCRs for SARS-CoV-2 may be the result of antigenic imprinting, such that preexisting CCC-specific memory T cells have reduced expansive capacity upon SARS-CoV-2 infection. Further studies are needed to determine how these crossreactive T cell responses affect clinical outcomes in COVID-19 patients.FUNDING NIH funding (U54CA260492, P30CA006973, P41EB028239, R01AI153349, R01AI145435-A1, R21AI149760, and U19A1088791) was provided by ...
Source: Journal of Clinical Investigation - May 18, 2021 Category: Biomedical Science Authors: Arbor G. Dykema, Boyang Zhang, Bezawit A. Woldemeskel, Caroline C. Garliss, Laurene S. Cheung, Dilshad Choudhury, Jiajia Zhang, Luis Aparicio, Sadhana Bom, Rufiaat Rashid, Justina X. Caushi, Emily Han-Chung Hsiue, Katherine Cascino, Elizabeth A. Thompson, Source Type: research

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

The year's new drugs and biologics 2020
Drugs Today (Barc). 2021 Feb;57(2):101-177. doi: 10.1358/dot.2021.57.2.3275929.ABSTRACT2020 will go down in history as a year marked in every respect by the emergence and astonishingly rapid spread of the first major global viral pandemic in a century. It seems like nearly every event or story of the year was influenced in some way by COVID-19, and in that respect, the year ended on a high note with the authorization for emergency use of the first vaccines to prevent SARS-CoV-2 infection and drugs to treat COVID-19. Despite the pandemic's dominance of the 2020 headlines, productivity was at a record high level across all t...
Source: Drugs of Today - March 3, 2021 Category: Drugs & Pharmacology Authors: A I Graul L A Sorbera Source Type: research

Pages: 1  2  3